ASCO Conference Coverage
Filter News By:
Featured News
View all
More News
(ESMO) June 25, 2019 - Results of the NEOSTAR and LCMC3 studies that tested neoadjuvant immune checkpoint blockade in resectable non-small cell lung cancer (NSCLC) were presented at 2019 ASCO Annual Meeting.
(Medscape Medical News) June 13, 2019 - The federal government's Oncology Care Model (OCM) is based on the idea that you can motivate clinicians with cash rewards to improve care and reduce costs.
(Xconomy San Diego) June 12, 2019 - Oncternal Therapeutics has joined the growing ranks of San Diego biotechs to go public, but it didn’t go through an IPO to get there.
(Medscape Medical News) June 10, 2019 - Ashley Glode, PharmD, a pharmacist in the gastrointestinal clinic at the University of Colorado Cancer Center, Anshutz, says marijuana is not a taboo topic in her state, where medical use was...
(Medscape Medical News) June 7, 2019 - Since the inception of the Open Payments program, fewer American medical oncologists appear to be engaging with industry, new findings show.
(Physician’s Weekly) June 5, 2019 - One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies.
(UNC LCCC) June 2, 2019 - Preliminary results from a University of North Carolina Lineberger Comprehensive Cancer Center study found that just 15 percent of a group of men in North Carolina with early-stage prostate cancer who choose...
(Washington Post/Bloomberg) June 5, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO), which wrapped up Tuesday, is one of the drug industry’s most prominent platforms for showcasing promising cancer research...
(The Center For Biosimilars) June 6, 2019 - During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers reported on the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980 (approved in the European...
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose...

OBR Tweets

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat…

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a…

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL…

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20